SK Bioscience

SK bioscience is a vaccine and bio company built on two pillars: sales of proprietary vaccines and contract development and manufacturing (CDMO). Its existing earnings base consists of in-house vaccines including the influenza vaccine SKYCellflu, the varicella vaccine SKYVaricella and the shingles vaccine SKYZoster.

Domestically the business is heavily public-procurement driven, as the company supplies its own influenza and varicella vaccines through the national immunization program (NIP), while its shingles vaccine is widely used in local government vaccination support schemes.

Overseas channels can be summarized by the company's statement that it was selected as a UNICEF influenza vaccine supplier for 2026 and began sequential shipment of a combined 640,000 doses across the southern and northern hemispheres, securing both major public procurement channels alongside its earlier mainstay PAHO.

For SKYVaricella, the company signed a technology transfer and local production facility agreement with Colombian state pharmaceutical firm VECOL.

The CDMO pillar is IDT Biologika, the German vaccine and biologics CDMO acquired in 2024 as a strategic investment to extend a proprietary-vaccine business model into global contract development and manufacturing.

The combination is showing up in actual contracts: for the second-generation Zaire Ebola vaccine pursued with MSD and Hilleman Laboratories, SK bioscience produces the drug substance while IDT handles drug product development and manufacturing under a contract signed in March 2026, and shortly before that the pair won a phase-one task in a next-generation vaccine initiative run by European health authorities (HaDEA under mandate from HERA), targeting a high-immunogenicity seasonal influenza vaccine for the elderly and a patch-type pandemic influenza vaccine.

On subsidiary scale, an August 2026 press report stated that IDT turned profitable in 2025 with revenue of KRW 465.7bn and operating profit of KRW 9.9bn, and posted revenue of KRW 129.5bn and operating profit of KRW 18.6bn in 2Q26.

Competitively, domestic influenza and varicella vaccines compete with other Korean vaccine makers in public tenders, while pneumococcal conjugate vaccines sit in a market long dominated by global majors, implying high development difficulty and entry barriers.

The earnings trajectory splits sharply around the COVID-19 period. In 2022 the company posted revenue of KRW 456.7bn, operating profit of KRW 115.0bn and a 25.2% operating margin; in 2023 revenue of KRW 369.5bn came with an operating loss of KRW 12.0bn, though net profit remained positive at KRW 22.3bn.

In 2024 revenue shrank to KRW 267.5bn while the operating loss widened to KRW 138.4bn, pushing the operating margin to -51.7%, with operating cash flow at minus KRW 128.0bn.

In 2025, with IDT consolidated for a full year, revenue reached KRW 651.4bn, roughly 2.4 times the prior year, the operating loss narrowed to KRW 123.5bn for a -19.0% margin, and operating cash flow swung to plus KRW 102.5bn.

Net loss attributable to owners nonetheless persisted at KRW 53.9bn in 2024 and KRW 57.4bn in 2025, while the acquisition-driven balance sheet shift lifted total liabilities from KRW 148.6bn in 2023 to KRW 918.3bn in 2025 and the debt-to-equity ratio from 8.7% to 45.1%.

Quarterly, the operating loss ran KRW 37.4bn in 2Q25, KRW 19.4bn in 3Q25, KRW 51.6bn in 4Q25 and KRW 44.5bn in 1Q26 before narrowing to KRW 15.7bn in 2Q26.

Notably, 3Q25 delivered positive net profit attributable to owners of KRW 24.5bn despite the operating loss, illustrating how non-operating items can swing quarterly bottom lines.

For the first half of 2026 combined, revenue was KRW 324.3bn with an operating loss of KRW 60.3bn: the top line edged up but the deficit widened, and the company cited the relocation of headquarters to Songdo early in the year and increased research and development spending as the reasons.

On the second-quarter revenue decline, management explained that part of its proprietary vaccine volume was deferred to the third quarter and that, with those volumes recognized in 3Q, the impact on full-year results should be limited.

Summing the four quarters from 3Q25 through 2Q26 gives revenue of about KRW 659.3bn, an operating loss of about KRW 131.3bn and a net loss attributable to owners of about KRW 84.7bn.

With the pandemic windfall gone, the vaccine industry has shifted to a phase where seasonal products, public procurement and late-stage pipeline outcomes determine results.

The pneumococcal vaccine market the company targets is projected by Evaluate Pharma to grow at a 4.7% compound annual rate from KRW 11.9tn in 2024 to KRW 14.2tn in 2028, and conjugate technology accounted for 94% of global pneumococcal vaccine sales as of 2023, making it the de facto standard.

The segment is dominated by global majors, but a stated differentiator is that GBP410 is the first candidate in infant Phase 3 trials to include more than 20 serotypes.

For domestic influenza vaccines, analysis notes that government procurement prices, vaccination rates, rival output and circulating virus shifts all matter, and that expansion of overseas public procurement volume will determine growth.

On the CDMO side, outsourcing demand from global pharma persists, while European manufacturing footprint and regulatory track record act as key competitive variables in winning orders.

On positioning, the company states it holds the world's first cell-culture influenza vaccine to obtain WHO prequalification, giving it a certification base usable in international agency tenders.

On the other hand, proprietary vaccine sales cluster in the vaccination season and CDMO revenue depends on client schedules, so commentary also warns that quarterly volatility is high and at least two to three more quarters of profit trends need to be observed.

The company's near-term plan is explicit.

It intends to accelerate earnings improvement in the second half through expansion of IDT's CDMO business and increased proprietary vaccine supply, while continuing clinical development of core pipeline assets including GBP410, and management added that volumes deferred from the second quarter will be fully recognized within the third quarter.

On late-stage timing, as of the May 2026 disclosure, global Phase 3 is underway and the company targets a top-line readout in the second half of next year while preparing for commercialization and building out production, placing the checkpoint in the second half of 2027.

The Phase 3 covers roughly 7,700 subjects aged six weeks to 17 years, with the company aiming to secure key results in the second half of 2027. On capacity, commercial production expansion at the Andong L HOUSE has been completed, adding manufacturing capability for global supply.

On funding, a total of KRW 300bn is provided as ultra-low-rate long-term borrowing and will be applied to GBP410 research and development, commercialization preparation and production upgrades, with the structure comprising KRW 250bn from the government advanced strategic industries fund and KRW 50bn from Korea Development Bank.

Because this is debt rather than equity, however, its impact on interest expense and leverage metrics also warrants monitoring. As for sell-side views, Heungkuk Securities was reported to have, in a May 2026 note, forecast a full-year operating loss of KRW 149.3bn and cut its target price to KRW 52,000 from KRW 60,000.